Background: Due to the heterogeneity of patients with Barcelona clinic liver cancer (BCLC) intermediate-stage hepatocellular carcinoma (HCC), Bolondi criteria were proposed and patients were divided into four substages. The purpose of this study was to compare the survival of substage B1 patients who were initially treated with a combination of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (TACE-RFA) or TACE alone.
Methods: 404 patients with stage B1 HCC were retrospectively analyzed from January 2005 to December 2012. 209 patients received TACE-RFA, and 195 received TACE alone as initial treatment. The overall survival (OS) and progression-free survival (PFS) rates were estimated by the Kaplan-Meier method and compared by the log-rank test.
Results: 1-, 3-, and 5-year OS rates were 83.7%, 45.8%, and 24.8% in the TACE-RFA group and 80.7%, 26.4%, and 16.7% in the TACE group, respectively (P=0.003). The corresponding PFS rates were 71.8%, 26.6%, and 13.0% and 59.1%, 11.0%, and 2.2% in the TACE-RFA group and TACE group, respectively (P < 0.001). Multivariate regression analysis indicated that tumor size (OS: hazard ratio (HR) = 0.683, P=0.001; PFS: HR = 0.761, P=0.013), along with treatment allocation (OS: HR = 0.701, P=0.003; PFS: HR = 0.620, P < 0.001), was the independent prognostic factor for both OS and PFS.
Conclusions: Combination TACE and RFA treatment yielded better survival than TACE alone for patients with stage B1 HCC according to the Bolondi criteria.
Copyright © 2019 Furong Liu et al.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular CarcinomaM Hirooka et al. AJR Am J Roentgenol 210 (4), 891-898. PMID 29412017.The indications for TACE-RFA may be expanding to BCLC-B HCC. For patients with disease classified as substages B1 and B2, TACE-RFA may be a better treatment modality than …
Improved Clinical Outcome Using Transarterial Chemoembolization Combined With Radiofrequency Ablation for Patients in Barcelona Clinic Liver Cancer Stage A or B Hepatocellular Carcinoma Regardless of Tumor Size: Results of a Single-Center Retrospective Case Control StudyY Ren et al. BMC Cancer 19 (1), 983. PMID 31640620.TACE-RFA had an advantage over TACE alone in prolonging PFS and improving OS in HCC patients with BCLC A/B, and can benefit patients regardless of tumor size.
Comparison of Transarterial Chemoembolization With Radiofrequency Ablation for Unresectable Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma: A Propensity Score MatchingRX Chen et al. J Gastroenterol Hepatol 31 (2), 442-9. PMID 26259976.Transarterial chemoembolization is an effective alternative treatment for unresectable BCLC stage 0/A HCC when RFA is not feasible.
Transarterial Chemoembolization in Hepatocellular Carcinoma Treatment: Barcelona Clinic Liver Cancer Staging SystemK Han et al. World J Gastroenterol 21 (36), 10327-35. PMID 26420959. - ReviewHepatocellular carcinoma (HCC), the fifth most common cancer that predominantly occurs in liver cirrhosis patients, requires staging systems to design treatments. The bar …
Comparison of Transarterial Chemoembolization Combined With Radiofrequency Ablation Therapy versus Surgical Resection for Early Hepatocellular CarcinomaPS Yi et al. Am Surg 84 (2), 282-288. PMID 29580359. - ReviewBoth radiofrequency ablation (RFA) and surgical resection (SR) are radical treatment recommended for early hepatocellular carcinoma (HCC). Transarterial chemoembolization …